（编辑 任世碧） 证券日报网讯 11月5日晚间，兴齐眼药发布关于2021年限制性股票激励计划第四个归属期归属结果暨股 份上市公告称，公司本次第二类限制性股票的归属数量为1，080，582股，占归属前公司总股本的 0.44%，归属人数为77人。本次第二类限制性股票的归属日为2025年11月7日。本次第二类限制性股票 上市流通日期为2025年11月7日，本次归属的限制性股票不设限售期。 ...

3、本次第二类限制性股票上市流通日为 2025 年 11 月 7 日，本次归属的限 制性股票不设限售期。 证券代码：300573 证券简称：兴齐眼药 公告编号：2025-056 沈阳兴齐眼药股份有限公司 关于 2021 年限制性股票激励计划 第四个归属期归属结果暨股份上市公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次第二类限制性股票的归属日为 2025 年 11 月 7 日。 2、本次第二类限制性股票的归属数量为 1,080,582 股，占归属前公司总股 本的 0.44%，归属人数为 77 人。 沈阳兴齐眼药股份有限公司于 2025 年 9 月 28 日召开的第五届董事会第十一 次会议审议通过了《关于公司 2021 年限制性股票激励计划第四个归属期归属条 件成就的议案》。近日，公司申请办理了 2021 年限制性股票激励计划第四个归属 期的登记工作，具体情况公告如下： 一、本次激励计划实施情况概要 （一）2021年限制性股票激励计划简介 公司分别于2021年8月26日召开的第四届董事会第五次会议及2021年9月13 日召开的202 ...

截至2025年10月31日收盘，兴齐眼药(300573)报收于80.21元，下跌3.73%，换手率12.22%，成交量23.04 万手，成交额18.69亿元。 董秘： 尊敬的投资者，您好。未来这两款产品上市后，将进一步优化公司近视防控产品矩阵，持续为 儿童青少年提供更全面的近视防控解决方案。感谢您的关注。 投资者： 您好，公司不同浓度硫酸阿托品滴眼液（0.02%和 0.04%）在药品审评中心（CDE）审评中， 请问评审通过了吗？该浓度滴眼液和0.01%浓度市场规模是否更大? 董秘： 尊敬的投资者，您好。公司不同浓度硫酸阿托品滴眼液（0.02%和 0.04%）目前正处于审评阶 段，后续达到信息披露标准时，公司将按照法律法规及相关规定，及时、准确地履行信息披露义务。不 同浓度的硫酸阿托品滴眼液在临床使用过程中能够更好的满足不同近视人群对近视控制的需求。 谢 谢。 投资者： 公司2025年三季度业绩非常好超预期，公司本次定增完成后是否考虑跟随国家战略去香港新 发H股？ 董秘： 尊敬的投资者，您好。公司暂无相关计划，感谢您的关注。 董秘最新回复 投资者： 请问，公司不同浓度硫酸阿托品滴眼液（0.02%和 0.04%） ...

Core Viewpoint - Xingqi Eye Pharmaceutical is a leading company in the domestic ophthalmic drug sector, focusing on research and development, with a competitive product lineup in the market [1] Financial Performance - For Q3 2025, Xingqi Eye Pharmaceutical reported revenue of 1.904 billion yuan, ranking 35th out of 110 in the industry, significantly lower than the top two competitors, East China Pharmaceutical (32.664 billion yuan) and Fosun Pharmaceutical (29.393 billion yuan), but above the industry average of 280 million yuan and median of 83.8 million yuan [2] - The net profit for the same period was 599 million yuan, ranking 14th in the industry, again lower than the leaders, but above the industry average of 299 million yuan and median of 78.29 million yuan [2] Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 23.24%, down from 25.53% year-on-year and below the industry average of 35.26%, indicating strong solvency [3] - The gross profit margin for Q3 2025 was 81.33%, an increase from 78.38% year-on-year and above the industry average of 57.17%, reflecting robust profitability [3] Executive Compensation - Chairman Liu Jidong's salary for 2024 was 6.001 million yuan, a slight increase from 6 million yuan in 2023 [4] - General Manager Gao E's salary for 2024 was 2.3202 million yuan, up from 2.079 million yuan in 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 16.85% to 54,100, with an average holding of 3,480.23 shares, a decrease of 14.42% [5] Growth Projections - According to Huazheng Securities, Xingqi Eye Pharmaceutical is expected to achieve revenues of 2.76 billion yuan, 3.65 billion yuan, and 4.57 billion yuan from 2025 to 2027, with respective year-on-year growth rates of 41.8%, 32.5%, and 25.1% [6] - Net profits for the same period are projected to be 760 million yuan, 1.1 billion yuan, and 1.43 billion yuan, with year-on-year growth rates of 123.7%, 45.2%, and 30.5% [6] Clinical Development - The company is advancing its pipeline with several new ophthalmic drugs, including SQ-129 vitreous sustained-release injection and SQ-22031 eye drops, which are in clinical trials [6][7] - The sales of core products, particularly low-concentration atropine eye drops, are expected to continue to grow [7]

Core Points - The Shanghai Composite Index fell by 0.81% on October 31, with 16 industries rising, led by the pharmaceutical and media sectors, which increased by 2.42% and 2.39% respectively [1] - The pharmaceutical sector saw a net inflow of 4.494 billion yuan, with 435 out of 477 stocks in the sector rising, and 11 hitting the daily limit [1] - The top three stocks with the highest net inflow in the pharmaceutical sector were Shuyou Shen (4.64 billion yuan), Lianhuan Pharmaceutical (3.49 billion yuan), and Zhongsheng Pharmaceutical (3.05 billion yuan) [1] Industry Summary - The pharmaceutical industry had a strong performance today, with a 2.42% increase and significant capital inflow [1] - The leading stocks in terms of capital inflow included: - Shuyou Shen: +19.99%, turnover rate 15.01%, capital flow 464.24 million yuan - Lianhuan Pharmaceutical: +10.01%, turnover rate 13.81%, capital flow 348.66 million yuan - Zhongsheng Pharmaceutical: +10.02%, turnover rate 10.14%, capital flow 304.73 million yuan [1] - Conversely, the stocks with the highest capital outflow included: - Xingqi Eye Medicine: -3.73%, turnover rate 12.22%, capital flow -177.64 million yuan - Heng Rui Medicine: +2.02%, turnover rate 1.31%, capital flow -101.30 million yuan - Gan Li Medicine: -2.75%, turnover rate 3.21%, capital flow -80.14 million yuan [2]

Core Viewpoint - The company is currently in the review stage for different concentrations of atropine sulfate eye drops (0.02% and 0.04%), which aim to better meet the needs of various myopic populations for myopia control [1] Group 1 - The company has stated that it will fulfill its information disclosure obligations in a timely and accurate manner once the products meet the disclosure standards [1] - The different concentrations of atropine sulfate eye drops are designed to cater to the varying needs of myopia control among different groups [1]

Core Viewpoint - The company has demonstrated significant revenue growth driven by its core products, cyclosporine eye drops and atropine sulfate eye drops, while implementing strategies to mitigate competitive pressures and optimize production capacity [1][2][3]. Group 1: Revenue Growth and Core Products - The company's revenue has consistently increased, with figures of 1.25 billion, 1.468 billion, and 1.943 billion from 2022 to 2024, and 536 million in Q1 2025, reflecting year-on-year growth rates of 32.42% and 53.24% [1]. - The net profit attributable to the parent company also rose, reaching 208 million, 240 million, 348 million, and 136 million during the same periods, with year-on-year increases of 44.54% and 285.96% [1]. - Cyclosporine eye drops, approved in June 2020 and included in the medical insurance directory in 2022, saw revenue growth from 448 million to 1.366 billion, projected to account for 100% of eye drop revenue in 2024 [1]. - Atropine sulfate eye drops, approved in March 2024, are the first product in China aimed at slowing the progression of myopia in children and are currently in a market monopoly phase [2]. Group 2: Competitive Landscape and Response Strategies - The industry is experiencing increased competition, with new products from companies like Hengrui Medicine and Kanghong Pharmaceutical expected to enter the market by mid-2025 [3]. - The company has established a comprehensive marketing system covering public hospitals, private eye care groups, retail pharmacies, and e-commerce platforms, with atropine eye drops available in approximately 17,000 retail pharmacies by mid-2025 [3]. - A professional promotion team of over 1,000 members has been formed, and core products have been included in more than 20 clinical guideline consensus documents [3]. - The company is expanding its research pipeline, with 78 projects under development, including 0.02%/0.04% concentration atropine and a biological agent for dry eye treatment [3]. Group 3: Production Capacity and Financial Health - The production capacity utilization rate for eye drops was 67.33% in 2024 and 60.37% in the first half of 2025, primarily due to new production lines ramping up and some outsourced production [4]. - The sales-to-production ratio remained high at 119.67% in the first half of 2025, indicating strong market demand [4]. - The company reported a decrease in accounts receivable turnover from 10.77 in 2022 to 8.94 in Q1 2025, but over 99% of accounts receivable are due within one year, with a collection rate of 93.73% [4]. - The company maintains a prudent approach to inventory management, with a provision for inventory impairment at 3.56%, higher than peers like Kanghong Pharmaceutical and Hengrui Medicine [4]. Group 4: R&D Investment and Future Plans - R&D expenditures from 2022 to 2024 were 190 million, 182 million, and 235 million, with capitalization ratios of 23.44%, 7.89%, and 6.22% respectively, primarily for clinical research on cyclosporine and atropine [5]. - As of June 2025, the company holds 73 invention patents and employs 271 R&D personnel, accounting for 11.17% of total staff [5]. - The company plans to raise 850 million through a private placement, with 650 million allocated for R&D center construction and 200 million for working capital, addressing current space constraints and aiming to add 280 R&D personnel over the next decade [6]. - The company clarified that adjustments to project investments were necessary due to rapid business growth, ensuring alignment with strategic planning without veering into real estate investments [6].

国泰海通证券股份有限公司 关于沈阳兴齐眼药股份有限公司 向特定对象发行股票并在创业板上市 上市保荐书 之 保荐机构（主承销商） （中国（上海）自由贸易试验区商城路 618 号） 二〇二五年十月 沈阳兴齐眼药股份有限公司 上市保荐书 声 明 本保荐机构及其保荐代表人已根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）等法 律法规和中国证券监督管理委员会（以下简称"中国证监会"）及深圳证券交易 所的有关规定，诚实守信，勤勉尽责，严格按照依法制定的业务规则和行业自律 规范出具上市保荐书，并保证所出具文件真实、准确、完整。 如无特殊说明，本上市保荐书中的简称或名词释义与《沈阳兴齐眼药股份有 限公司向特定对象股票并在创业板上市募集说明书》（申报稿）一致。 沈阳兴齐眼药股份有限公司 上市保荐书 一、发行人基本情况 （一）发行人基本信息 | 公司名称 | 沈阳兴齐眼药股份有限公司 | | --- | --- | | 英文名称 | SHENYANG XINGQI PHARMACEUTICAL CO., LTD. | | 股本 | 245,348,945 股 | | 股 ...

特此公告。 集说明书等申请文件修订的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 沈阳兴齐眼药股份有限公司（以下简称"公司"）于 9 月 15 日收到深圳证券 交易所（以下简称"深交所"）出具的《关于沈阳兴齐眼药股份有限公司申请向 特定对象发行股票的审核问询函》（审核函〔2025〕020049 号）（以下简称"审 核问询函"），深交所发行上市审核机构对公司向特定对象发行股票的申请文件进 行了审核，并形成了审核问询问题。 公司收到审核问询函后，会同相关中介机构对审核问询函所列问题进行逐项 回复和说明，同时鉴于公司 2025 年半年度报告已公开披露，公司会同相关中介 机构对募集说明书等申请文件进行补充和更新，具体内容详见公司在巨潮资讯网 （http://www.cninfo.com.cn）披露的相关文件。审核问询函的回复披露后，公司 将通过深交所发行上市审核业务系统报送相关文件。 公司本次向特定对象发行股票事项尚需通过深交所审核，并获得中国证券监 督管理委员会（以下简称"中国证监会"）作出同意注册的决定后方可实施。本 次向特定对象发行股票事项最终能否 ...

证券代码：300573 证券简称：兴齐眼药 沈阳兴齐眼药股份有限公司 （中国（辽宁）自由贸易试验区沈阳片区新运河路 25 号） 向特定对象发行股票并在创业板上市 募集说明书（申报稿） 保荐人（主承销商） （中国（上海）自由贸易试验区商城路 618 号） 二〇二五年十月 沈阳兴齐眼药股份有限公司 向特定对象发行股票募集说明书 声 明 1、公司及董事会全体成员保证本募集说明书内容真实、准确、完整，并确 认不存在虚假记载、误导性陈述或重大遗漏。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 2、本募集说明书按照《上市公司证券发行注册管理办法》《公开发行证券 的公司信息披露内容与格式准则第 61 号——上市公司向特定对象发行证券募集 说明书和发行情况报告书》等要求编制。 本募集说明书是公司董事会对本次向特定对象发行股票的说明，任何与之相 反的声明均属不实陈述。 3、中国证监会、深圳证券交易所对本次发行所做的任何决定或意见，均不 表明其对申请文件及所披露信息的真实性、准确性、完整性做出保证，也不表明 其对发行人的盈利能力、投资价值或者对投资者的收益做出实质性判断或保证。 任何 ...